PET scan to image PDE4B in people with Alzheimer’s disease or mild cognitive impairment
Official title: PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)
Run by National Institutes of Health Clinical Center (CC) · NCT07169630 · Data updated 2026-11-12
We will test whether a new PET tracer can measure PDE4B levels in the brains of people aged 50 and older with Alzheimer's or mild cognitive impairment compared with healthy volunteers.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 100 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | lecanemab, radiation, methotrexate |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | November 15, 2026 |
| Main results expected | April 11, 2029 |
| Study ends | April 11, 2030 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT07169630 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults aged 50 or older either diagnosed by a neurologist or psychiatrist with Alzheimer’s disease or mild cognitive impairment (Aβ-positive) or age-matched healthy volunteers (Aβ-negative), who can consent (or have an LAR) and are in generally good health.
✕Probably not a fit
People with advanced comorbid medical conditions, contraindications to PET/MRI, or whose cognitive symptoms are not related to Aβ pathology are unlikely to gain direct clinical benefit from this imaging research.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1 interventional study uses the radiotracer [18F]PF-06445974 to measure PDE4B in the brain and compares people aged 50+ with AD or MCI to age- and sex-matched healthy volunteers. Participants undergo two PET scans (one for PDE4B and one for beta-amyloid), one brain MRI, up to five clinic visits, physical exams, blood tests, and neuropsychological testing. Primary analyses compare PDE4B binding in the medial temporal lobe between Aβ-positive AD/MCI participants and Aβ-negative controls, with exploratory correlations to clinical and plasma biomarkers including Aβ40, Aβ42, total tau, and P-tau217. The study is conducted at the NIH Clinical Center and focuses on safety and imaging signal characterization in a small, well-screened cohort.
Why it matters
Potential benefit: If successful, the PET tracer could provide a new imaging biomarker of neuroinflammation that helps identify or track Alzheimer's-related changes and guide treatments.
How similar studies have gone: Other PET ligands have imaged neuroinflammation in neurodegenerative disease, but imaging PDE4B with [18F]PF-06445974 is relatively novel and has limited prior human data.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Participants will be referred by a physician with the suspected diagnosis of AD or MCI. However, the PI of this protocol will provide the final diagnosis. For this reason, this protocol will have just one consent form for participants suspected of having either AD or MCI. AD and MCI Study Groups: Participants must meet all the following criteria: * Aged 50 or older. * Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document. * Have been diagnosed by a neurologist or psychiatrist with MCI or AD. * Be in good general health as evidenced by medical history and physical examination. * Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. * Agree to adhere to the lifestyle considerations. Healthy Volunteers: Participants must meet all the following criteria: * Aged 50 or older. * Able to provide informed consent. * Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment. * Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. * Agree to adhere to the lifestyle considerations. EXCLUSION CRITERIA: Both the study groups will be excluded if they meet any of the following criteria: * Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). * Participants should not have taken non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month. * Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities. * Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). * Are unable to travel to the NIH. * Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. * Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the volunteer and/or caregiver during the screening visit. * Participants must not have substance use disorder or alcohol use disorder. * Participants should not be under treatment or previously treated with an amyloid antibody such as lecanemab. * Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye). * Pregnancy or breast feeding. * HIV infection. * Non-English speaking participants. Exclusion of Children: Inclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit. Exclusion of Pregnant or Breastfeeding Women: Pregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will not require contraception for this protocol to allow participants autonomy in medical decision-making. However, while we will not require contraception for woman of childbearing potential, we will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant Exclusion of Participants who are HIV Positive: Persons with HIV infection are excluded because HIV infection itself may change cAMP signaling. Exclusion of Non-English-Speaking Participants: Non-English-speaking participants will be excluded from participation in this study because neuropsychological testing is required by this protocol. This testing, which is critical for interpreting study results, has not been validated in other languages or when using a translator.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Paul A Parcon, M.D. — National Institute of Mental Health (NIMH)
- Study coordinator: Tara N Turon, C.R.N.P.
- Email: tara.turon@nih.gov
- Phone: (301) 827-6599
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Choose Myself (Before) Losing Myself
We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
VR pupillometry to detect cognitive impairment
This project will try VR-based eye-tracking pupillometry to see if pupil responses can detect and track cognitive problems in adults with Alzheimer's, mild cognitive impairment, depression-related cognitive impairment, or no cognitive issues.
-
Using Wearables to Find Clues About Mild Cognitive Impairment and Early Alzheimer’s
Researchers are testing whether wearable devices worn in daily life can help identify people 65 and older who might have mild cognitive impairment or early Alzheimer’s disease.
-
Investigating biomarkers related to Alzheimer's disease and cognitive impairment
This study is trying to see how blood tests and brain scans relate to Alzheimer's disease and memory issues in older adults aged 60 to 90.
-
Time-restricted eating intervention for Alzheimer's disease
This study is testing if eating only during a 14-hour window at night can help people with Mild Cognitive Impairment or early Alzheimer's disease think better and sleep more soundly.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.